Our previous work showed that in T98G cells, a human glioblastoma multiforme-derived cell line, the association of c-Fos to the endoplasmic reticulum (ER) and consequently, the capacity of c-Fos to activate phospholipid synthesis, is regulated by the phosphorylation state of tyrosine (tyr) residues #10 and #30 of c-Fos. The small amount of c-Fos present in quiescent cells is tyrphosphorylated, is dissociated from the ER membranes and does not activate phospholipid synthesis. However, on induction of the cell to re-enter growth, c-Fos expression is rapidly induced, it is found dephosphorylated, associated to ER membranes and activating phospholipid synthesis (Portal et al., 2007) . Herein, using in vivo and in vitro experimental strategies, we show that the kinase c-Src is capable of phosphorylating tyr residues of c-Fos whereas the phosphatase TC45 T-cell protein-tyr phosphatase (TC-PTP) dephosphorylates them, thus enabling c-Fos/ER association and activation of phospholipid synthesis. Results also suggest that the regulation of the phosphorylation/dephosphorylation cycle of c-Fos occurs at the TC-PTP level: induction of cells to re-enter growth promotes the translocation of TC45 from a nuclear to a cytoplasmic location concomitant with its activation. Activated TC45 in its turn promotes dephosphorylation of pre-formed c-Fos, enabling cells to rapidly activate phospholipid synthesis to respond to its growth demands.
Introduction
The expression of the proto-oncoprotein c-Fos is very tightly regulated responding rapidly and transiently to a plethora of stimuli (Angel and Karin, 1991; Morgan and Curran, 1995; Caputto and Guido, 2000) . c-Fos heterodimerizes with proteins of the jun family to form some of the many AP-1 transcription factors that regulate the expression of target genes among which are genes involved in the initiation of DNA synthesis as a response to growth factors (Kouzarides and Ziff, 1989; Angel and Karin, 1991) . A precise molecular understanding of the participation of AP-1 in complex processes such as proliferation and growth has not yet been achieved in spite of having been described >20 years ago and of the many studies directed toward establishing the target genes of the different AP-1 dimers.
Results from our laboratory have disclosed that in addition to its nuclear activity, c-Fos exerts a cytoplasmic activity: it associates to components of the endoplasmic reticulum (ER) where the main cellular production of phospholipids takes place, and activates their synthesis. c-Fos-ER association and consequently the capacity of c-Fos to activate phospholipid synthesis, is regulated by the phosphorylation state of tyrosine (tyr) residues #10 and #30 of c-Fos: quiescent cells contain small amounts of c-Fos, which is tyr-phosphorylated and is neither associated to the ER membranes nor does it activate phospholipid synthesis. However, on induction of cells to re-enter growth, c-Fos expression rapidly increases, c-Fos is dephosphorylated and is found associated to the ER membranes and capable of activating phospholipid synthesis (Portal et al., 2007) .
The c-Fos-dependent activation of lipid synthesis has been implicated in cell differentiation, proliferation and growth. This lipid-activating capacity of c-Fos has been observed in vivo in events related to the neuronal activity of chick retina ganglion and photoreceptor cells (Guido et al., 1996; Bussolino et al., 1998; de Arriba Zerpa et al., 1999) and also in culture in NIH3T3 cells induced to re-enter growth (Bussolino et al., 2001) and in PC12 cells induced to differentiate (Gil et al., 2004; Crespo et al., 2008) . The biological relevance of c-Fos-dependent lipid synthesis activation was underscored in human brain malignant tumor cells that express abundant c-Fos, contrasting with a non-detectable expression of this protein in normal human brain specimens. Furthermore, in these tumors, c-Fos is associated to ER components and activates phospholipid synthesis as compared with normal specimens. In accordance, in an animal model of Neurofibromatosis Type I, the NPcis mouse that spontaneously develops nervous system tumors, tumor development depends on c-Fos expression: no tumors develop in NPcis mice knock out for c-Fos contrasting with a tumor burden 470% in their NPcis littermate animals, with no significant modifications in the AP-1 content (Silvestre et al., 2010) . In line with these observations is our finding that in T98G cells, impairing tyr-dephosphorylation before inducing cells to re-enter growth results in accumulation of phosphorylated c-Fos, no c-Fos-dependent phospholipid synthesis activation and inhibition of cell proliferation (Portal et al., 2007) .
The reversible phosphorylation state of protein tyr residues catalyzed by the coordinated action of protein kinases and protein-tyr phosphatases (PTPs) is crucial for controlling proliferation, differentiation, survival and metabolism (Hunter, 2000) , all processes in which cFos participates (Angel and Karin, 1991; Gil et al., 2004; Silvestre et al., 2010) . The aim of this work was to identify the kinases(s) and phosphatase(s) responsible for regulating c-Fos tyr-phosphorylation, c-Fos/ER association and consequently, c-Fos-dependent phospholipid synthesis activation. We found that cytoplasmic c-Src (Oppermann et al., 1979) phosphorylates cFos and that the 45 Kd-variant of Human T-cell protein-tyr phosphatase (TC-PTP) (Cool et al., 1989) dephosphorylates c-Fos tyr-residues #10 and #30. Results indicate that activation of TC-PTP on stimulation of cells to re-enter growth promotes c-Fos dephosphorylation, enabling pre-formed c-Fos to associate to the ER membranes and rapidly activate lipid synthesis in response to the growth stimulus.
Results

Recombinant c-Src phosphorylates c-Fos in vitro
An in silico study using the Human Protein Reference Database to identify possible kinases(s) responsible for phosphorylating c-Fos tyr residues shed two putative kinases: the epidermal growth factor receptor and c-Src. As c-Fos has been found in the cell nucleus (Morgan and Curran, 1995) and in the vicinity of or associated to ER membrane components (Bussolino et al., 2001; Gil et al., 2004; Silvestre et al., 2010) and c-Src has been localized to the perinuclear region of the cell (Frame, 2002) , we investigated if c-Src is a kinase that recognizes c-Fos as one of its substrates to phosphorylate it on tyr residues.
c-Src was assayed to determine its capacity to phosphorylate c-Fos in vitro (Cooper et al., 1984) by incubation of recombinant c-Src with c-Fos. Incubates were immunoblotted with anti-P-Tyr (P-Tyr) antibody. Incubation of c-Fos with c-Src results in the tyr phosphorylation of c-Fos (Figure 1 ). In parallel, we examined if c-Src phosphorylates the c-Fos mutant Y10/ 30F in which tyr residues #10 and #30 are substituted by non-phosphorylatable phenylalanine. Phosphorylation of Y10/30F was negligible (Figure 1) indicating that in vitro, c-Fos phosphorylation by c-Src occurs on the two tyr residues previously found phosphorylated in vivo (Portal et al., 2007) .
Endogenous c-Src phosphorylates c-Fos in vitro
To determine if endogenous c-Src is also capable of phosphorylating c-Fos in vitro, T98G cell lysates were subjected to immunoprecipitation (IP) with a c-Src antibody and IP c-Src activity was determined in vitro with recombinant c-Fos as substrate. To gain information on the possible regulatory mechanism imposed by cells on c-Fos phosphorylation, the activity of endogenous c-Src from quiescent cells was examined to see if an activation or inhibition of c-Src activity is promoted by the growth conditions.
As observed with recombinant c-Src in Figure 1 , endogenous c-Src also phosphorylates c-Fos as was evidenced after 5 min of incubation (Figure 2a, upper panel) . Noticeably, no differences were found between c-Src activity in quiescent (zero time) and stimulated cells ( þ fetal bovine serum (FBS) for 7.5 or 60 min) at any incubation time examined (Figure 2a, upper panel) . The middle and lower panels of Figure 2a are loading controls of c-Fos and c-Src, respectively, assayed in the upper panel.
Apart from demonstrating that c-Src is capable of phosphorylating c-Fos in vitro, results indicate that its activity toward c-Fos is the same independently of the cells' growth conditions. To discard that the apparent lack of regulation of c-Src-phosphorylation of c-Fos was due to some modification in endogenous c-Src that could turn it insensitive to the growth conditions, the c-Src phosphorylating activity of another well-described c-Src substrate, enolase (Hu et al., 2007) , was determined. The activity of IP c-Src on enolase is clearly activated on inducting cells to re-enter growth (Figure 2b , first row). Taken together, these results suggest that the regulation of the phosphorylation state of c-Fos is not associated with cell growthdependent fluctuations in c-Src kinase activity. (Figure 3a ) and to the fact that after culturing cells for 48 h -FBS to attain quiescence, most of the c-Fos contained by the cells is already phosphorylated and dissociated from the ER membranes (Portal et al., 2007) . c-Fos phosphorylated by c-Src no longer activates phospholipid synthesis It was considered of interest to know if phosphorylation of c-Fos by c-Src in vitro modifies its capacity to activate phospholipid synthesis. For this, we assayed the capacity to activate phospholipid synthesis of c-Srcphosphorylated c-Fos (P-c-Fos), its non-phosphorylatable mutant Y10/30F and of Y10/30E, a phosphomimetic version of c-Fos in which glutamic acid residues substitute for tyr residues #10 and #30. c-Fos and the Y10/30F mutant were first subjected to the c-Src phosphorylation procedure described under Figure 1 . Then, these proteins were assayed to determine their in vitro capacity to activate phospholipid synthesis as described under Figure 4 . Y10/30F not incubated with c-Src and c-Src incubated without any added substrates were run as controls. Figure 4 shows that neither recombinant c-Fos phosphorylated in vitro by c-Src or the phosphomimetic mutant Y10/30E increase phospholipid synthesis above control levels. By contrast, non-phosphorylatable Y10/30F, treated or not with c-Src, has the same capacity to activate phospholipid synthesis as c-Fos. c-Src alone does not modify phospholipid synthesis. These results indicate that for c-Fos to activate phospholipid synthesis, both tyr residues #10 and #30 must be devoid of an acidic residue such as that conferred by the phosphate residues or, in Y10/30E, by glutamic acid, an acidic amino acid.
c-Fos-and Y10/30F-but not Y10/30E-expressing cells show activated phospholipid synthesis and progress through the cell cycle To determine if c-Fos activation of phospholipid synthesis is relevant for cell proliferation, quiescent T98G cells were transfected to express c-Fos or Y10/30E or Y10/30F or were cultured in the presence of sense (SO) or anti-sense (ASO) c-Fos mRNA oligonucleotide. Figure 5 shows that phospholipid synthesis is activated in cells cultured 30 h þ FBS to induce c-Fos expression (black columns 3 and 4). This was also so in those transfected to express c-Fos or Y10/30F and primed 9 h þ FBS (black columns 7 and 8). By contrast, cells transfected to express Y10/30E and primed 9 h þ FBS showed levels of phospholipid synthesis comparable to those cultured the 30 h -FBS (compare black columns 6 with 1) or to non-transfected cells primed 9 h þ FBS (black column 2). Cells cultured 30 h þ FBS, þ ASO, showed no phospholipid synthesis activation (column 5).
Cell proliferation strictly correlates with the condition of activated phospholipid synthesis. Figure 5 shows that cells primed 9 h þ FBS and then cultured -FBS to complete 30 h proliferate only if phospholipid synthesis is activated, that is, in cells transfected to express c-Fos (column 7) or Y10/30F (column 8). Cells in which c-Fos expression is impaired with ASO (column 5) or express the phosphomimetic version of c-Fos, Y10/30E (column 6) neither activate phospholipid synthesis (black columns) or proliferate (grey columns). 
TC-PTP dephosphorylates c-Fos
The Human Protein Reference Database was used to identify putative phosphatase(s) that may dephosphorylate c-Fos. This in silico analysis yielded the family of TC-PTP's as putative c-Fos phosphatases. Two forms of human TC-PTP with identical catalytic domains but different non-catalytic C-terminal domains have been described: a 48-kDa form (TC48) that is targeted to the ER by a stretch of hydrophobic residues at the extreme C terminus, and a 45-kDa variant (TC45) that lacks the hydrophobic C-terminal tail and is targeted to the nucleus by an atypical bipartite nuclear localization sequence (Lorenzen et al., 1995; Tiganis et al., 1997; Ibarra-Sanchez et al., 2000) . TC45 exits the nucleus in response to specific stimuli to dephosphorylate distinct substrates thus regulating specific signalling pathways (Tiganis et al., 1998 (Tiganis et al., , 1999 Tiganis, 2002) .
T98G cells were examined for the presence of transcripts of the TC45 and TC48 isoforms of TC-PTP's by reverse transcriptase-PCR. The analysis was carried out in quiescent cells and in cells stimulated with FBS for 5 or 60 min, times at which cells contain predominantly dephosphorylated c-Fos (Portal et al., 2007) . Figure 7a (left panel) shows that only the TC45 mRNA isoform is present in these cells and no apparent The capacity to activate phospholipid synthesis of recombinant c-Fos, c-Fos phosphorylated by purified c-Src (P-c-Fos), the phosphomimetic Y10/30E mutant of c-Fos and the non-phosphorylatable mutant of c-Fos Y10/30F was examined as described previously (Gil et al., 2004) . Briefly, 32 P-phospholipid labelling capacity of quiescent cells was determined in vitro by the addition of 100 mg of quiescent cell homogenate to the assay medium containing in a final vol of 80 ml, 140 mM NaCl, 4.5 mM KCl, 0.5 mM MgCl 2 , 5.6 mM glucose, 64 mM HEPES buffer pH 7.4 and 3 mC of [32] P-ATP (spec.act. 3000 Ci/mmol; PerkinElmer Life Sciences) plus 1ngr of either recombinant c-Fos protein, P-c-Fos, Y10/30F, or Y10/30E/mg of homogenate protein. Incubations were for 90 min at 37 1C.
32 P-phospholipid quantification was performed as described previously (Guido and Caputto, 1990) . Results expressed as c.p.m. of 32 P incorporated into phospholipids/mg of protein are the mean ± s.d. of three experiments performed in triplicate; *Po0.002 with respect to control (buffer) as determined by Student's two-tailed t-test. Y10/30F not incubated with c-Src and c-Src incubated without any added substrates were run as controls. Note that the presence of c-Src in the assays did not modify phospholipid synthesis.
induction of its expression is promoted when cells are stimulated to grow with FBS for 5 or 60 min as also evidenced in the quantification to the right. No TC48-mRNA could be detected either in quiescent or growing cells at any time examined (Figure 7a, middle panel) . Consequently, the studies that followed were focused on determining the capacity of TC45 to dephosphorylate c-Fos in vitro and in vivo.
To examine the capacity of purified TC45 to dephosphorylate P-c-Fos in vitro, c-Fos was first phosphorylated by incubation in the presence of recombinant c-Src as described in Figure 1 and incubates subjected to western blot using anti-P-Tyr antibody to control c-Fos tyr-phosphorylation (Figure 7b , left panel, first row). Membranes were stripped, washed thoroughly with Tris buffered saline and incubated in the presence ( þ TC45) or the absence (-TC45) of recombinant TC45. Membranes were then incubated with anti-P-Tyr antibody to examine the phosphorylation state of c-Fos. It was found that TC45 significantly dephosphorylates c-Fos as compared with control assays run in parallel in the absence of TC45 (Figure 7b , left panel, compare lanes 3 and 4 and quantification to the right).
The capacity of c-Fos to activate phospholipid synthesis according to its phosphorylated state was also examined. As expected considering the results of Figure 4 , P-c-Fos has no lipid synthesis-activating capacity, but is restored on treatment with TC45 ( Figure 7c , compare second and forth columns). A control was run to discard that the presence of TC45 in the assays was modifying phospholipid labelling rates (Figure 7c , last column).
c-Fos and TC45 co-IP Several cellular substrates of TC45 have been identified including the epidermal growth factor receptor, the adaptor protein p52Shc (Tiganis et al., 1998 (Tiganis et al., , 1999 Klingler-Hoffmann et al., 2001) , the Janus family of kinases 1 and 3 (Simoncic et al., 2002) and the signal transducer and transcription activator, STAT1 (Aoki and Matsuda, 2002; Yamamoto et al., 2002) . To the best of our knowledge, c-Fos has not yet been considered a possible substrate of TC45. To confirm that TC45 is indeed capable of interacting with c-Fos, cells were double transfected with HA-tagged c-Fos and myctagged TC45 or with a point mutated substrate-trapping version of TC45, D182A (Tiganis et al., 1998) , also myctagged. D182A has an Asp/Ala mutation about 30 amino acids N-terminal of the catalytic HCSAG motif (Wa¨lchli et al., 2000) . Like its wt counterpart TC45, D182A forms an enzyme-substrate intermediate involving the interaction of the conserved phosphatase cysteine with the tyr phosphate of the substrate forming a stable complex that, at difference with TC45, is unable to release the dephosphorylated substrate.
Cells were double transfected 48 h before harvesting and immunocomplex formation between TC45 or D182A with c-Fos was examined both in quiescent and in cells induced to grow by addition of FBS for 15 min. Figure 8A shows that c-Fos co-IP with both P (black columns) and also for cell proliferation (grey columns). Cells were primed to proliferate by feeding with FBS during 9 h, time at which medium was changed to fresh medium -FBS (columns 2, 6-8) or þ FBS (columns 3-5) and þ ASO (column 5) or þ SO (column 4), added to the medium 3 h before initiating cell priming by FBS addition. Column 1 corresponds to cells incubated the 30-h -FBS. Phospholipid labelling was determined as described previously (Guido and Caputto, 1990 ) after pulsing cells with TC45 and D182A although more immunocomplex formation was observed with D182A. Comparison of immunocomplex formation between growing and quiescent cells evidenced that the amount of c-Fos/TC45 and c-Fos/D182A immunocomplex formation in growing cells was higher than in quiescent ones ( Figure 8A, top  row) . Quantification of c-Fos/PTP immunocomplex formation shown in the right panel of Figure 8A evidenced a B2 Â increase in growing with respect to quiescent cells, both with TC45 and with D182A. The bottom panel of Figure 8A is a c-myc-PTP and HA-cFos loading control.
Cellular localization of HA-c-Fos and green fluorescent protein-tagged D182A and of the ER marker GRP78 was examined by immunofluorescence in quiescent and growing, co-transfected cells. Figure 8B shows the expected translocation of D182A from a preponderantly nuclear localization in quiescent cells (panel c) to a cytoplasmic one in cells cultured þ FBS for 15 min (panel d) (Galic et al., 2003) . Importantly, translocated cytoplasmic D182A shows clear colocalization sites with c-Fos in þ FBS cells (inset to panel d); cFos also colocalizes with the ER marker (inset to panel f). Figure 8B (panel h) shows colocalization sites of the three markers examined in þ FBS cells.
TC45 activity is substantial for dephosphorylating c-Fos
This activity is regulated according to the physiological state of the cell. To determine the contribution of TC45 to the total phosphatase activity in T98G cells that may dephosphorylate c-Fos, TC45 activity was blocked by transfecting cells with micro-RNA against TC45 (miR-TC45) 48 h before cell harvesting and the presence of Pc-Fos determined. As a control, a plasmid that does not affect TC45 expression (miR-Neg) was transfected in parallel. miR-TC45 was effective in impairing TC45 expression as compared with control cells grown in the absence of miR-TC45 (-miR-TC45 cells) (Figure 9a Figure 9b .
In vitro phospholipid labelling capacity of cells treated as in Figure 9b was also examined but in the presence of cycloheximide to avoid induction of c-Fos expression on FBS addition. As expected, activated phospholipid synthesis was found only in homogenates containing dephosphorylated c-Fos (lane 2, Figure 9c ).
To confirm that mitogens that induce c-Fos expression also activate TC45 activity, we determined the activity of TC45 present in lysates prepared from quiescent cells and compared it with that from cells induced to grow for the last 15 min before harvesting. TC45 from þ FBS cells (Figure 9d , top row, lane 2) was found more active to dephosphorylate P-c-Fos in vitro than that from quiescent (-FBS) cells (Figure 9d , top row, lane 1). To the left is the quantification of the remnant P-c-Fos with respect to c-Fos after treatment with TC45 from -FBS and þ FBS cells. Loading controls for c-Fos and TC45 are shown on middle and bottom rows of the left panel of Figure 9d .
Discussion
It seems reasonable to expect a rigorous control on the capacity of c-Fos to activate phospholipid synthesis because of the importance it has on the metabolic outcome of a cell: c-Fos can be activating or not the synthesis of lipids and consequently can increase or not the rate of membrane biogenesis. This control may be achieved either by controlling the expression of this protein or by controlling its capacity to activate lipid synthesis. The induction of c-Fos expression in response to extracellular stimuli is a well-recognized characteristic of c-Fos and has been extensively documented (reviewed in Angel and Karin, 1991; Morgan and Curran, 1995; Caputto and Guido, 2000) . As the cellular responses to extracellular stimuli must be rapid, the de novo synthesis of proteins, in this case of c-Fos, appears at first sight as an event too slow to elicit a rapid response in the cell. On the other hand, reversible phosphorylation/ dephosphorylation of proteins has emerged as a fundamental molecular switch that is much less time consuming than protein synthesis for rapid cell activation (Hunter, 2009 ). In the case of c-Fos, a body of information showing that both levels of control are operating during mitogen-dependent cell activation is emerging.
Herein, we have identified the first kinase and the first phosphatase capable of phosphorylating and dephosphorylating tyr residues of c-Fos. Information has also been obtained that indicates that the regulation of this reversible post-translational modification of c-Fos is imposed on the de-phosphorylation step rather than on the phosphorylation one. It has been shown that induction of cells to re-enter growth promotes the translocation of TC45 from the nucleus to the cytoplasm (Figure 8 ) and the concomitant activation of this phosphatase (Figure 9 ). Regarding c-Src regulation, in spite that many details of the activation of this kinase have emerged during the past years (reviewed in Hunter, 2009 ), basal activity seems sufficient to maintain the basal levels of c-Fos found in quiescent cells in its phosphorylated state (Figure 2) .
In fact, that the regulation of the phenomenon is on the dephosphorylation step seems reasonable because dephosphorylation rather than phosphorylation will enable the cell to activate the signalling pathway leading to an increase in membrane biogenesis in response to extracellular mitogenic stimuli: dephosphorylated rather than phosphorylated c-Fos activates phospholipid synthesis. Consequently, cells could maintain phosphorylation of c-Fos constitutively activated so that the cell is metabolically arrested but ready to rapidly respond to growth stimuli. The more prolonged response of the cell would be achieved through the induction of the de novo synthesis of c-Fos, the other proposed mechanism to control c-Fos lipid-activating capacity. So, it can be envisaged a phosphorylation/dephosphorylation cycle of c-Fos as the rapid cell response to mitogen stimulation followed by the activation of the de novo synthesis of c-Fos to maintain the cells in a metabolically activated state. It still remains to be determined if the newly synthesized c-Fos also enters the phosphorylation/dephosphorylation cycle. It is hypothesized that the ) were fed cycloheximide (50 mg/ml culture medium) for 30 min before changing medium to fresh medium containing or not FBS for 15 min as indicated; then cells were harvested and assayed for in vitro phospholipid synthesis capacity. Results are the mean c.p.m./mg protein of 32 P incorporated into phospholipids±s.d. of three experiments performed in triplicate; *Po0.002 with respect to lane 1, as determined by Student's two-tailed t-test. (d) Cell lysates prepared from quiescent (ÀFBS) and growing cells ( þ FBS for 15 min) were subjected to IP for TC45 and phosphatase activity determined using purified P-c-Fos. Incubates were subjected to SDS-PAGE and WB using anti-P-tyr (upper row) and anti c-Fos (lower row) antibodies. To the right are the optical density ratios of P-c-Fos/c-Fos. Results are the mean ratios±s.d. of three experiments; *Po0.001 as determined by Student's two-tailed t-test. Note the higher phosphatase activity of TC45 obtained from growing cells as compared with that in quiescent cells. A control of IP TC45 added to each incubate is shown in the last row of Figure 9d . entry or not of c-Fos into the cycle when cells are metabolically activated is stochastic whereas tyr-phosphorylation of c-Fos could increase the half-life of this protein and in this way determine its fate either to degradation when not phosphorylated or to form the small pool of phosphorylated c-Fos contained in quiescent cells. Future studies are needed to clarify this aspect of the phenomenon.
Mitogen stimulation results in the post-translational activation of TC45 PTP. However, little is known about the molecular mechanism involved in this activation. It is clear, however, that part of the activation mechanism includes its translocation from its nuclear localization to the cytoplasm. In this case, translocation would enable its interaction with c-Fos to catalytically de-phosphorylate it. One regulatory mechanism reported for TC45 is on its positively charged C-terminus that negatively regulates its activity; a truncation mutant lacking this region is constitutively active (Hao et al., 1997) . TC45 is also activated by the collagen-binding integrin a1b1, which selectively interacts with the N-terminal of TC45, activating it in response to collagen adhesion (Mattila et al., 2005) whereas reversible oxidation inactivates TC45 (Meng et al., 2004) . It will be of key interest to determine precisely the activation mechanism for TC45 because in this case, PTP acts as a proto-oncogene rather than a tumor-suppressor gene as has been reported for diverse PTPs (reviewed in Julien et al., 2011) .
Together, these results support the notion that mitogen stimulation commands the activation of previously formed but inactive c-Fos because of its tyrphosphorylated state thus promoting a rapid metabolic response in the cell. This first wave of response is followed by a second, more prolonged wave of metabolic stimulation achieved by the induction of the de novo synthesis of c-Fos (Gil et al., 2004; Portal et al., 2007) . Both responses would converge to assure the activation of the cell metabolic machinery to enable high rates of membrane biogenesis.
Materials and methods
Cell culture conditions, transfections and extract preparation NIH3T3 wt, knock-out for c-Src or for SYF and T98G cells (ATCC, Bethesda, MD, USA) were grown under standard culture conditions in Dulbecco's modified Eagle medium (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS. After desired confluence, growth was continued for 48 h in the absence of FBS to achieve quiescence. Cells were induced to reenter growth by addition of 10% FBS ( þ FBS) for the time indicated in each case or continued to be cultured -FBS until harvesting.
Cell transfections were performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. For harvesting, cells were rinsed twice with ice-cold 10 mM phosphate-buffered saline (PBS) and harvested in modified RIPA buffer (50 mM Tris HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 1% Nonidet P-40) for WB and IP analysis or in PBS for phospholipid analysis. Cell proliferatio´n was determined with CyQUANT NF Cell Proliferation Assay Kit (Invitrogen).
Electrophoresis, WB and IP assays Cell lysates (10 mg) or IP's were fractionated through sodium dodecyl sulfate-containing polyacrylamide gels (12%) and electrotransferred at 300 mA during 1 h. Immuno-detection of c-Fos, Y10/30F, Y10/30E, TC-PTP, c-Src, P-tyr, HA and c-myc flag were carried at room temperature by blocking of membranes with 10 mM TBS containing 5% non-fat dried milk for 1 h, followed by incubation with c-Fos antibody (1/5000, Sigma-Aldrich, St Louis, MO, USA), TC-PTP antibody (1/500, Biosciences, Santa Cruz, CA, USA), c-Src antibody (1/500, eBioscience, San Diego, CA, USA), PY20 mAb (1/1000, Sigma-Aldrich), HA antibody (1/2000, SigmaAldrich) or c-myc antibody (1/1000, Sigma-Aldrich) overnight at 4 1C in TBS, 0.1% Tween 20. Membranes were washed three times (10 min) with TBS-Tween 20 and incubated 2 h at room temperature with IRDye 800CW goat anti-mouse secondary antibody or IRDye 800CW goat anti-rabbit secondary antibody (1/25000, LI-COR Bioscience, Lincoln, NE, USA). Membranes were washed and immuno-detection performed using ODYSSEY Infrared Imaging System (LI-COR Bioscience). For IP assays, 500 mg of total protein was subjected to IP with the desired antibody during 3 h at 4 1C, washed, cleared by centrifugation and the procedure continued as indicated in each case. When required, precipitates were recovered in Laemmli loading buffer.
In culture phospholipid labelling To determine 32 P-phospholipid labelling in culture, T98G cells, transiently transfected to express c-Fos or its mutants Y10/30E or Y10/30F or not transfected, were grown an additional 48 h in the absence of FBS to attain quiescence. c-Fos ASO or SO oligonulceotides were added to the medium 3 h before FBS addition, as indicated (Gil et al., 2004) . Cells were pulsed with 50 mCi/ml 32 P-orthophosphate (PerkinElmer Life Sciences, Boston, MA, USA) the last 2 h before harvesting and 32 Pphospholipid labelling determined (Guido and Caputto, 1990) .
In vitro phospholipid labelling In vitro phospholipid labelling by T98G cell homogenates was as described previously (Gil et al., 2004) . Briefly, reactions were initiated by addition of 100 mg of cell homogenate and stopped by the addition of trichloroacetic acid and phosphotungstic acid (5-0.5% w/v, respectively).
Purification of recombinant proteins
His-tagged c-Fos (pDS56-HisFos), Y10/30F, Y10/30E (pET15b) were expressed as described previously . Expression plasmids for c-Src and TC45, were kindly provided by MA Seeliger and H Charbonneau, respectively. Protein determination was according to Bradford, 1976 .
Phosphorylation and dephosphorylation assays
To phosphorylate c-Fos, 2 mg of recombinant c-Fos were incubated with 5 ng/ml of recombinant c-Src in 30 ml of kinase buffer (20 mM Hepes pH 7.4, 1 mM MgCl 2 , 1 mM DTT and 30 mM ATP). Incubations were for 30 min at 301C and reactions stopped by the addition of 3X SB. To determine endogenous c-Src activity, 2 ug of c-Fos or enolase were incubated with c-Src IP as indicated above; phosphorylation was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and WB as described.
To determine phosphatase activity, membranes containing P-c-Fos were incubated in 1 ml phosphatase buffer (25 mM imidazol, 0.1% b-mercapto-ethanol) plus 2 ng/ml of recombi-nant TC45 for 30 min at 301C; membranes were washed five times with TBS and bands visualized with PY20 antibody as described above. To determine endogenous TC45 activity, 2 mg of P-c-Fos were incubated with TC45 IP as indicated above.
Immunofluorescence microscopy Cells grown on poly-Lysine (1 g/ml)-coated coverslips were rinsed twice with ice-cold 10 mM PBS and fixed in 3% (w/v) paraformaldehyde, 4% (w/v) sucrose in PBS 10 mM at 37 1C for 10 min. Washed cells were permeabilized with 0.25% Triton x-100 in PBS for 10 min at 37 1C, washed and blocked with blocking buffer (1% bovine serum albumin in 10 mM PBS) for 2 h and incubated over-night at 4 1C in blocking buffer containing c-Fos antibody (1/500), c-Src antibody (1/300), HA-antibody (1/500) and/or GRP78 antibody (1/300, Santa Cruz Biosciences) as indicated. Cells were then washed twice in 10 mM PBS, 0.1% Tween 20 and incubated with Alexa 546 anti-mouse antibody, Alexa 633 anti-rabbit antibody and/or Alexa 488 anti-rabbit antibody (1/1000, Molecular Probes, Eugene, OR, USA). Coverslips were mounted with FluorSave (Calbiochem, San Diego, CA, USA) and visualized with a 100 Â objective using a Olympus FV1000 or Pascal 5 laser scanning confocal microscope using Olympus (Center Valley, PA, USA) or Carl Zeiss (St Louis, MO, USA) software, respectively, for image analysis.
Reverse transcriptase-PCR, constructs and site directed mutagenesis T98G total RNA was isolated following Trizol protocol (Invitrogen); 2 mg was used for reverse transcription with oligo dT primers according to M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) using the following primers: TC45 or TC48 Fow 5 0 -CGGGATCCATGCCCACCACCA TCGA-3 0 ; TC45 Rev 5 0 -GGAATTCCAGGTGTCTGTCAATCTTGG CCT-3 0 ; TC48 Rev 5 0 -GGAATTCCATAGGGCATTTTGCTGAA AAAACAGTC-3 0 .
Plasmids containing TC45 wt or TC45-D182A kindly provided by T Tiganis were cloned in pCDNA3.1b (Invitrogen) in BamHI y EcoRI site, and in pEGFP-N3 (Clontech, USA) in BglII y EcoRI site, using the primers described above.
The BLOCK-iT Pol II miR RNAi Expression Vector Kit (Invitrogen) was used to clone miRNA sequence contained within the engineered pre-miRNA into pcDNA 6.2-GW/ EmGFP-miR expression vector to generate expression clone miR-TC45. The miRNA oligo used as top strand was 5 0 -TGCT GTTTAGAGGAAAGTCCTGTACAGTTTTGGCCACTGAC TGACTGTACAGGTTTCCTCTAAA-3 0 . c-Fos tyr residues #10 and #30 were mutated over pDS56His-Fos by the circular mutagenesis method (Sambrook and Russel, 2001 ).
